Bluebird Bio shares are trading higher after the company reported better-than-expected Q1 EPS results. The company also announced it amended its existing co-development agreement with Bristol Myers Squibb. Bristol Myers Squibb will buy out its obligation to pay future ex-U.S. milestones and royalty payments for $200 million.
Benzinga Newsdesk